Thirty-two outbreaks of hepatitis A associated with drinking water were identified during 1971 to 2017, and all occurred before 2010.
Direct-acting antiviral therapy may be a beneficial therapy for patients infected with HCV with a history of hepatocellular carcinoma by increasing overall survival.
Patients with porphyria cutanea tarda have increased all-cause mortality and risk for death because of gastrointestinal diseases and cancer of the gut, liver, gallbladder, and lungs.
FDA reports rare cases of worsening liver function or liver failure in patients with chronic hepatitis C virus (HCV) who had moderate-to-severe liver impairment and were treated with Mavyret, Zepatier, or Vosevi, despite these drugs being contraindicated in this group of patients.
In people with HIV, the kynurenine/tryptophan (kyn/trp) ratio is elevated and is associated with greater liver fibrosis.
The FDA has granted Breakthrough Therapy designation to peginterferon lambda (Lambda; Eiger BioPharmaceuticals) for the treatment of hepatitis delta virus (HDV) infection.
Draft recommendation statement expands screening to asymptomatic individuals aged 18 to 79 years
Among patients with hepatitis C virus (HCV) infection and complete response to hepatocellular carcinoma (HCC) treatment, direct-acting antiviral (DAA) therapy is associated with a significant reduction in the risk for death.
In Spain, researchers found data from a real-world cohort that showed that retreatment and a sustained viral response, depending upon treatment nonresponse and genotype, can be achieved with certain combinations of direct-acting antivirals.
The researchers found that lipophilic statin users had a significantly lower 10-year HCC risk compared with matched nonusers (8.1 versus 3.3 percent; absolute risk difference [RD], −4.8 percent; adjusted subdistribution hazard ratio [aHR], 0.56; 95 percent confidence interval [CI], 0.41 to 0.79), while hydrophilic statin users did not have a lower risk (8.0 versus 6.8 percent; RD, −1.2 percent; aHR, 0.95; 95 percent CI, 0.86 to 1.08).
Measuring liver stiffness may be a feasible community screening tool to predict liver-related adverse events.
Researchers in Australia found that treatment with direct acting antivirals for hepatitis C in the primary care setting is effective in treatment uptake in people who inject drugs, compared with referrals to hospital-based services.
Investigators analyzed the relationship between HIV, hepatitis C virus, and peripheral artery disease in women.
Researchers found data that showed hepatitis C virus infection is linked to an increased risk for diabetes mellitus in both chronic hepatitis patients and patients with cirrhosis from hepatitis C.
By 2014, less than one-third of individuals aged 18 to 49 years who were at risk for hepatitis B virus exhibited hepatitis B surface antibody levels indicative of protection.
Fibronectin may be a potential marker for hepatitis B surface antigen seroclearance.
The novel method of lateral flow immunoassay may be a cost-effective way to identify patients with chronic hepatitis B virus infection.
Optimized, commercial enzyme immunoassays may be able to diagnose hepatitis B virus using oral fluid samples.
The United States Preventative Service Task Force has issued a statement that reaffirms its 2009 recommendations for screening pregnant women for hepatitis B virus.